Alliance Pharma PLC Appointment of Non-Executive Director (3940D)
June 29 2021 - 1:00AM
UK Regulatory
TIDMAPH
RNS Number : 3940D
Alliance Pharma PLC
29 June 2021
For immediate release 29 June 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Appointment of Non-Executive Director
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces that Kristof Neirynck, a highly experienced
consumer brands executive, will join the Group on 1 December 2021
as an independent Non-Executive Director.
Kristof is currently Group Vice-President and Chief Marketing
Officer Global Brands at Walgreens-Boots-Alliance (WBA), a global
leader in retail pharmacy. He brings almost 20 years of
international consumer brand experience including complex
omni-channel business models, direct-to-consumer strategies and
cross border e-commerce into China.
Kristof started his career in 2002 at Procter & Gamble in
Belgium before moving to Procter & Gamble International in
Switzerland in 2004 and working there for 11 years. He joined WBA
in 2015 as Vice-President & Global Category Director Skin Care
before being appointed to his current role in 2017. In this role,
he has global responsibility for the portfolio of more than 20
WBA-owned brands across Beauty and Consumer Healthcare,
representing more than $4bn in sales.
Following the departure of Nigel Clifford, who left the Group on
30 April 2021, Kristof's appointment brings the number of
independent Non-Executive Directors back to four.
David Cook, Alliance Pharma's Chairman, said: "I am delighted to
confirm the appointment of Kristof as a Non-Executive Director of
Alliance and we look forward to his joining the Group on 1 December
this year. Kristof brings outstanding operational and strategic
experience of the consumer healthcare market, gained at global
businesses. His international, omni-channel and marketing
experience is highly complementary to the skillset of the existing
Board members as we focus on the Group's international
expansion."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Kristof Leon Neirynck
(43 years of age) has not been a director or partner of any
companies during the five years preceding the date of this
announcement. There is no further information to be disclosed
pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules
for Companies.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Oliver Steele
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with subsidiaries in Europe, the Far
East and the US and wide international reach through an extensive
network of distributors, generating sales in more than 100
countries.
We hold the marketing rights to around 80 Consumer Healthcare
brands and Prescription Medicines, which are managed on a portfolio
basis according to their growth potential. Promotional investment
is focused primarily on our Consumer healthcare brands, many of
which have significant international or multi-territory reach. Our
Prescription Medicines are generally sold in a more limited number
of local markets, and most require little or no promotional
investment.
Our strategy allows us to deliver good organic growth and to
enhance our growth rate through carefully selected
acquisitions.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABIGDLUDDDGBI
(END) Dow Jones Newswires
June 29, 2021 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024